Genovate Biotechnology Co (ROCO:4130) Other Current Liabilities: NT$37.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
67 GF Score
Price NT$26.70
GF Value NT$19.99
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Genovate Biotechnology Co Other Current Liabilities?

Genovate Biotechnology Co ROCO:4130 67 Other Current Liabilities is NT$37.2 Mil as of Mar. 2026. GuruFocus rates ROCO:4130 with a GF Score™ of 67/100 and a GF Value™ of NT$19.99 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Genovate Biotechnology Co's other current liabilities for the quarter that ended in Mar. 2026 was NT$37.2 Mil.

Genovate Biotechnology Co's quarterly other current liabilities declined from Sep. 2025 (NT$37.4 Mil) to Dec. 2025 (NT$37.3 Mil) and declined from Dec. 2025 (NT$37.3 Mil) to Mar. 2026 (NT$37.2 Mil).

Genovate Biotechnology Co's annual other current liabilities declined from Dec. 2023 (NT$31.1 Mil) to Dec. 2024 (NT$28.4 Mil) but then increased from Dec. 2024 (NT$28.4 Mil) to Dec. 2025 (NT$37.3 Mil).

Genovate Biotechnology Co Other Current Liabilities Related Terms

Genovate Biotechnology Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Other Current Liabilities Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.57 24.39 31.11 28.41 37.27

Genovate Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.92 37.18 37.36 37.27 37.19
ROCO:4130
67GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of NT$37.2 Mil mean?
Genovate Biotechnology Co (ROCO:4130) has a Other Current Liabilities of NT$37.2 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genovate Biotechnology Co.
Is Genovate Biotechnology Co's Other Current Liabilities too high?
Genovate Biotechnology Co's current Other Current Liabilities is NT$37.2 Mil. Overall, Genovate Biotechnology Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Other Current Liabilities compare to VRTX and REGN?
Genovate Biotechnology Co's Other Current Liabilities of NT$37.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genovate Biotechnology Co. Genovate Biotechnology Co's current Other Current Liabilities is NT$37.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.99, compared to a current price of NT$26.70 — trading 33.6% above its estimated fair value. The current Other Current Liabilities is NT$37.2 Mil. Genovate Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Other Current Liabilities is NT$37.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.70 is trading 33.6% above its estimated GF Value™ of NT$19.99. GuruFocus considers Genovate Biotechnology Co to be Significantly Overvalued.

Key valuation signals for ROCO:4130:

  • Other Current Liabilities: NT$37.2 Mil
  • GF Value™: NT$19.99 vs. price of NT$26.70 (33.6% above fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
67GF Score

Get the complete analysis for ROCO:4130

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.70
Price
NT$19.99
GF Value